'Objective response rate' diaporamas de présentation

new moves

1.03k views • 85 slides

Building on the Success of Targeted Therapies in Metastatic Disease

Building on the Success of Targeted Therapies in Metastatic Disease. Harold J. Burstein, MD, PhD Assistant Professor of Medicine Department of Oncology Dana-Farber Cancer Institute Boston, Massachusetts. Trastuzumab. Monoclonal antibody binding to HER2/neu (erbB2) receptor

900 views • 67 slides

Moderator Neil Love, MD

727 views • 59 slides

RUOLO DELLA TERAPIA ANTIANGIOGENICA NEL CARCINOMA MAMMARIO Rilevanza delle Evidenze Scientifiche

RUOLO DELLA TERAPIA ANTIANGIOGENICA NEL CARCINOMA MAMMARIO Rilevanza delle Evidenze Scientifiche. P Pronzato Modena, 18.11.2011. (Anti-) Angiogenesis. [TITLE]. [TITLE]. HER2- Metastatic Breast Cancer (CT Needed) Decision Making Problems. F Cardoso & J Cortes. F Cardoso & J Cortes.

767 views • 54 slides

555 views • 52 slides

IRESSA: A journey of experience from broad to biomarker populations

IRESSA: A journey of experience from broad to biomarker populations. Claire Watkins Global Product Statistician, AstraZeneca EFSPI meeting on Oncology Basel, 24 th June 2010. Outline. A brief history of IRESSA (gefitinib) Lessons learned

1.29k views • 41 slides

The Changing Direction of Cancer Care

The Changing Direction of Cancer Care. Patricia Mucci LoRusso, D.O. Director Phase I Clinical Trials Program Karmanos Cancer Institute Detroit, MI. Cancer Statistics. Approximately 3400 people are diagnosed each day of cancer in the United States Approximately 142 cases in Michigan each day

498 views • 30 slides

Introduction

RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer.

388 views • 26 slides

CoPrincipal Investigators Herbert Juergens Paul Meyers Shreyaskumar Patel

SARC013/NO21158 SARC Global Collaboration: Phase 3 trial of R1507 in combination with cyclophosphamide/topotecan versus cyclophosphamide/topotecan alone for treatment of first recurrence Ewing sarcoma . CoPrincipal Investigators Herbert Juergens Paul Meyers Shreyaskumar Patel. SARC013/NO21158.

401 views • 11 slides

Advanced NSCLC

Advanced NSCLC. Objective response rate Well defined & widely accepted Does not correlate well with OS May be more useful if SD included Higher RR correlates with sx benefit. Advanced NSCLC. Time to tumor progression Poorly defined, not standardized

335 views • 11 slides